A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Sulfasalazine (Azulfidine)

Aminosalicylate class · 4 generic manufacturers · 5 ANDAs filed at FDA.

First FDA approval1950-06-20
Generic availableYes · 4 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$29.2M in CY2024 Part D spend877K claims · 273K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.197/unit
14 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.209
Across all dosage forms in distribution.
Highest NADAC
$0.278
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Sulfasalazine used for?

Sulfasalazine is a Aminosalicylate medication tracked in Medicare Part D.

Is there a generic for Sulfasalazine?

Yes. 5 ANDAs filed at FDA, 4 generic manufacturers currently shipping.

How much does my plan pay for Sulfasalazine?

Across 329 Part D plans, Sulfasalazine averages $0.209/unit (NADAC). Lowest available: $0.197/unit. Highest in distribution: $0.278/unit.

Is Sulfasalazine on the FDA shortage list?

No. Sulfasalazine is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Aminosalicylate2 alternatives in D1
01
Balsalazide Disodium
Aminosalicylate
$0.372Lowest NADAC
5Generic mfrs
$27.8MCY24 Part D spend
Compare →
02
Mesalamine
Brand: APRISO
$0.104Lowest NADAC
23Generic mfrs
$454.7MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (7 approvals on file) · NADAC unit costs: CMS NADAC weekly file (14 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.